Incidence and clinical course of femoral localized periosteal thickening and atypical femoral fracture over a 10-year period in patients with autoimmune inflammatory rheumatic disease
Authors:
- Hiroe SatoHSHiroe Sato
- Naoki KondoNKNaoki Kondo
- Yoichi KurosawaYKYoichi Kurosawa
- Eriko HasegawaEHEriko Hasegawa
- Ayako WakamatsuAWAyako Wakamatsu
- Yukiko NozawaYNYukiko Nozawa
- Daisuke KobayashiDKDaisuke Kobayashi
- Takeshi NakatsueTNTakeshi Nakatsue
- Yoko WadaYWYoko Wada
- Junichiro James KazamaJKJunichiro James Kazama
- Takeshi KurodaTKTakeshi Kuroda
- Masaaki NakanoMNMasaaki Nakano
Open Access
- 10 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 8 (9) , ziae090
Abstract
Atypical femoral fracture (AFF) is generally a rare complication of long-term use of bisphosphonate (BP); glucocorticoid (GC) use and Asian race are also risk factors. Femoral localized periosteal thickening (LPT, also termed “beaking”) of the lateral cortex often precedes AFF. This cohort study investigated the incidence of LPT and AFF and their clinical courses over 10 yr in patients with autoimmune inflammatory rheumatic diseases (AIRDs) treated with BP and GC. The study population consisted of 121 patients with AIRDs taking BP and GC. LPT was screened by X-ray, and the LPT shape was evaluated. Prednisolone (PSL) dose was 10 (8–12) mg/d at enrollment and 9 (6–10) mg/d at the last observation. LPT was evident in 10 patients at enrollment and increased linearly to 31 patients (26%) at the last observation. AFF occurred in 9 femurs of 5 patients with LPT. All patients with AFF had bilateral LPT, and the prevalence of pointed type and LPT height were higher in the AFF-positive group than in the AFF-negative group. AFF occurred before BP discontinuation in 2 patients, 1 yr after BP discontinuation in 1, after BP discontinuation followed by 7 yr of alfacalcidol use in 1, and after switching from alfacalcidol to denosumab in 1. The prevalence rates of AFF and LPT associated with long-term BP use with concomitant use of GC (mostly PSL ≥ 6 mg/d) in Japanese patients with AIRD increased over time. The selection of long-term osteoporosis treatment for LPT-positive patients is difficult in some cases.Keywords
This publication has 46 references indexed in Scilit:
- The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonatesOsteoporosis International, 2015
- The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trialsOsteoporosis International, 2015
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2015
- The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignmentBone, 2014
- The incidence of and risk factors for developing atypical femoral fractures in JapanJournal of Bone and Mineral Metabolism, 2014
- Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 updateJournal of Bone and Mineral Metabolism, 2014
- Incomplete Atypical Femoral Fractures: Assessing the Diagnostic Utility of DXA by Extending Femur LengthJournal of Clinical Densitometry, 2013
- Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2013
- Bisphosphonate Use and Atypical Fractures of the Femoral ShaftNew England Journal of Medicine, 2011
- Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatiteBone, 2006